Biased Ligands. Better Drugs.

TRV027 Phase 1 FTIH study summary

First human dosing experience with TRV027, a novel therapy for acute heart failure. Presented at 2012 Heart Failure of America Society meeting

David Soergel, Ruth Ann Subach, Jonathan Violin, Dennis Yamashita, Maxine Gowen, and Michael Lark

View PDF

Copyright © Trevena, Inc.